Medical Condition

schizophrenia

Total Trials

25

Recruiting Now

25

Trial Phases

Phase 3, Phase 2, Phase 1

Schizophrenia trials have been revitalized by the approval of muscarinic receptor agonists (xanomeline-trospium/KarXT) — the first non-dopaminergic antipsychotic approved in decades — validating a long-hypothesized cholinergic mechanism and opening new mechanistic territory. Negative symptom treatment and cognitive impairment associated with schizophrenia (CIAS) remain critical unmet needs with no approved therapies.

Active trials investigate M1/M4 muscarinic agonists, trace amine-associated receptor 1 (TAAR1) agonists (ulotaront), glycine transporter inhibitors, cognitive remediation combined with pharmacotherapy, and long-acting injectable formulations to improve adherence. PANSS total score and negative symptom subscales are standard primary endpoints.

Frequently Asked Questions — schizophrenia Clinical Trials

How many clinical trials are currently recruiting for schizophrenia?

ClinicalMetric currently tracks 25 actively recruiting clinical trials for schizophrenia, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 25. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.

What trial phases are available for schizophrenia?

schizophrenia research spans Phase 1 (3 trials), Phase 2 (5 trials), Phase 3 (2 trials), Phase 4 (2 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.

How do I find out if I qualify for a schizophrenia clinical trial?

Eligibility criteria for schizophrenia trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.

Trial Phases

Phase 1

Phase 2

Phase 3

Phase 4

Top Sponsors

Neurocrine Biosciences 3 trials

Otsuka Pharmaceutical Co., Ltd. 1 trial

Massachusetts General Hospital 1 trial

BC Mental Health and Addictions Research Institute 1 trial

Lithuanian University of Health Sciences 1 trial

schizophrenia

Frequently Asked Questions — schizophrenia Clinical Trials

Recruiting Clinical Trials

A Long-term Administration Trial of SEP-363856 in Patients With Schizophrenia

Transcranial Direct Current Stimulation (tDCS) Neuromodulation of Executive Function Across Neuropsychiatric Populations

Brain Health and Exercise in Schizophrenia

Validation of the Lithuanian Version of the BNSS, CDSS, and the SCoRS

Time and Virtual Reality in Schizophrenia and Bipolar Disorder

Search for Novel Transcranial Magnetic Stimulation (TMS) Targets for Mental Illness

Dimensional and Developmental Profiles of Psychosis in Children and Adolescents

Evaluation of the Efficacy of Transcranial Magnetic Stimulation on Resistant Auditory Hallucinations in Schizophrenia

Combination of NMDA-enhancing and Antioxidant Treatments for Schizophrenia

Benefits of Combining MCT With CR in the Recovery of Patients With Psychotic Spectrum Disorders

Medial-prefrontal Enhancement During Schizophrenia Systems Imaging

Cerebellar Stimulation and Cognitive Control

Study of the Safety, Tolerability, Pharmacokinetics and Food Effects of VV119 Capsules in Chinese Healthy Volunteers

Magnetic Seizure Therapy for Schizophrenia - Trial

Insight Into Hippocampal Neuroplasticity in Schizophrenia by Investigating Molecular Pathways During Physical Training

Genetics of Cannabis Use Disorder and Cannabinoid Response in Humans

Decision-Making in Schizophrenia: A Combined Neuroimaging and Experience Sampling Study

Efficacy of NBI-1117568 in Preventing Relapse in Adults With Schizophrenia

Cromoglicate Adjunctive Therapy for Outpatients With Schizophrenia

A Study to Assess Adverse Events, Change in Disease Activity, and How Oral Emraclidine Moves Through the Body in Adult Participants With Schizophrenia

Evaluation of NBI-1117570 in Inpatient Adults With Schizophrenia

Time Prediction and Cerebellum: Magnetic Transcranial Stimulation (TMS) in Healthy Volunteers

Smoking Cessation With Varenicline in Schizophrenia: Antipsychotic-Induced Neurological Symptoms as Correlates

A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor

Precision Brain Stimulation to Reduce Cannabis Craving in Schizophrenia